Clinical Evaluation of P21 Activated Kinase 1 (PAK1) Activation in Gliomas and Its Effect on Cell Proliferation

References

• Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res. 2014;6:149–70.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2–S8. doi:10.1188/16.CJON.S1.2-8.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu G, Quan X. Analysis of the factors affecting the prognosis of glioma patients. Open Med (Wars). 2019;14(1):331–5. doi:10.1515/med-2019-0031.
   PubMedGoogle Scholar
• Thotakura M, Tirumalasetti N, Krishna R. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Cancer Res Ther. 2014;10(3):641–5.
   PubMed Web of Science ®Google Scholar
• Osuka S, Van Meir EG. Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest. 2017;127(2):415–26. doi:10.1172/JCI89587.
   PubMed Web of Science ®Google Scholar
• Sim HW, Morgan ER, Mason WP. Contemporary management of high-grade gliomas. CNS Oncol. 2018;7(1):51–65. doi:10.2217/cns-2017-0026.
   PubMedGoogle Scholar
• Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29(12):5171–84.
   PubMed Web of Science ®Google Scholar
• Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol. 2011;5(4):374–86. doi:10.1016/j.molonc.2011.05.001.
   PubMed Web of Science ®Google Scholar
• Han X, Xue X, Zhou H, Zhang G. A molecular view of the radioresistance of gliomas. Oncotarget. 2017;8(59):100931–41. doi:10.18632/oncotarget.21753.
   PubMedGoogle Scholar
• Ye DZ, Field J. PAK signaling in cancer. Cell Logist. 2012;2(2):105–16. doi:10.4161/cl.21882.
   PubMedGoogle Scholar
• Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007;29(4):356–70. doi:10.1002/bies.20558.
   PubMed Web of Science ®Google Scholar
• Johnson DI. Cdc42: an essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev. 1999;63(1):54–105. doi:10.1128/MMBR.63.1.54-105.1999.
   PubMed Web of Science ®Google Scholar
• Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 1998;273(43):28238–46. doi:10.1074/jbc.273.43.28238.
   PubMed Web of Science ®Google Scholar
• Leisner TM, Liu M, Jaffer ZM, Chernoff J, Parise LV. Essential role of CIB1 in regulating PAK1 activation and cell migration. J Cell Biol. 2005;170(3):465–76. doi:10.1083/jcb.200502090.
   PubMed Web of Science ®Google Scholar
• Sells MA, Boyd JT, Chernoff J. p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol. 1999;145(4):837–49. doi:10.1083/jcb.145.4.837.
   PubMed Web of Science ®Google Scholar
• Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, et al. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007;13(22 Pt1):6603–9. doi:10.1158/1078-0432.CCR-07-0145.
   PubMed Web of Science ®Google Scholar
• Huynh N, Shulkes A, Baldwin G, He H. Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer. Cancer Biol Ther. 2016;17(8):813–23. doi:10.1080/15384047.2016.1195045.
   PubMed Web of Science ®Google Scholar
• Ito M, Codony-Servat C, Karachaliou N, Rosell R. Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(5):667–73. doi:10.21037/tlcr.2019.08.25.
   PubMed Web of Science ®Google Scholar
• Prudnikova TY, Villamar-Cruz O, Rawat SJ, Cai KQ, Chernoff J. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene. 2016;35(17):2178–85. doi:10.1038/onc.2015.278.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Iyer G, Solit DB, Glickman MS. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res. 2013;73(3):1156–67. doi:10.1158/0008-5472.CAN-12-1882.
   PubMed Web of Science ®Google Scholar
• Sharim J, Tashjian R, Golzy N, Pouratian N. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. J Clin Neurosci. 2016;30:166–8. doi:10.1016/j.jocn.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, Du J, et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012;31(29):3397–408. doi:10.1038/onc.2011.515.
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Liu GC, Peng L, Zhang C, Jia YM, Yang WH, Mao L. Effect of PAK1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines MHCC97-H and HepG2 and cells in xenograft tumor. Gene Ther. 2018;25(4):284–96. doi:10.1038/s41434-018-0016-9.
   PubMed Web of Science ®Google Scholar
• Rayala SK, Molli PR, Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res. 2006;66(12):5985–8. doi:10.1158/0008-5472.CAN-06-0978.
   PubMed Web of Science ®Google Scholar
• Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, et al. PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin Cancer Res. 2013;19(5):1106–15. doi:10.1158/1078-0432.CCR-12-1060.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, et al. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015;6:e1637. doi:10.1038/cddis.2015.2.
   PubMed Web of Science ®Google Scholar
• Jagadeeshan S, Subramanian A, Tentu S, Beesetti S, Singhal M, Raghavan S, et al. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer. Ann Oncol. 2016;27(8):1546–56. doi:10.1093/annonc/mdw184.
   PubMed Web of Science ®Google Scholar
• Chen MJ, Wu DW, Wang YC, Chen CY, Lee H. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via beta-catenin-mediated stemness. Sci Rep. 2016;6(1):34933. doi:10.1038/srep38463.
   PubMedGoogle Scholar
• Kim E, Youn H, Kwon T, Son B, Kang J, Yang HJ, et al. PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells. Cancer Res. 2014;74(19):5520–31. doi:10.1158/0008-5472.CAN-14-0735.
   PubMedGoogle Scholar
• Fang F, Pan J, Li YP, Li G, Xu LX, Su GH, et al. p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: a systematic review and meta-analysis. Oncotarget. 2016;7(19):27422–9. doi:10.18632/oncotarget.8320.
   PubMedGoogle Scholar
• Nikolic M, Chou MM, Lu W, Mayer BJ, Tsai LH. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature. 1998;395(6698):194–8. doi:10.1038/26034.
   PubMed Web of Science ®Google Scholar
• Rashid T, Banerjee M, Nikolic M. Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology. J Biol Chem. 2001;276(52):49043–52. doi:10.1074/jbc.M105599200.
   PubMed Web of Science ®Google Scholar
• Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–72. doi:10.3892/mmr.2014.2914.
   PubMed Web of Science ®Google Scholar
• King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemmings BA, Bokoch GM. p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). J Biol Chem. 2000;275(52):41201–9. doi:10.1074/jbc.M006553200.
   PubMed Web of Science ®Google Scholar
• Parrini MC. Untangling the complexity of PAK1 dynamics: the future challenge. Cell Logist. 2012;2(2):78–83. doi:10.4161/cl.19817.
   PubMedGoogle Scholar
• Osaki LH, Gama P. MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci. 2013;14(5):10143–61. doi:10.3390/ijms140510143.
   PubMed Web of Science ®Google Scholar
• Roig J, Traugh JA. p21-activated protein kinase gamma-PAK is activated by ionizing radiation and other DNA-damaging agents. Similarities and differences to alpha-PAK. J Biol Chem. 1999;274(44):31119–22. doi:10.1074/jbc.274.44.31119.
   PubMed Web of Science ®Google Scholar
• Perez-Yepez EA, Saldivar-Ceron HI, Villamar-Cruz O, Perez-Plasencia C, Arias-Romero LE. p21 Activated kinase 1: nuclear activity and its role during DNA damage repair. DNA Repair (Amst)). 2018;65:42–6. doi:10.1016/j.dnarep.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997;79(6):1195–202. doi:10.1002/(SICI)1097-0142(19970315)79:6<1195::AID-CNCR19>3.0.CO;2-V.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892–9. doi:10.1158/0008-5472.CAN-04-1337.
   PubMed Web of Science ®Google Scholar
• Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26(2):239–44. doi:10.1016/0360-3016(93)90203-8.
   PubMed Web of Science ®Google Scholar
• Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA. Ki-67 labeling index in glioblastoma; does it really matter? Hematol Oncol Stem Cell Ther. 2019;12(2):82–8. doi:10.1016/j.hemonc.2018.11.001.
   PubMedGoogle Scholar
• Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017;134(3):505–12. doi:10.1007/s11060-017-2379-y.
   PubMed Web of Science ®Google Scholar
• Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem. 2004;279(2):1422–8. doi:10.1074/jbc.M309937200.
   PubMed Web of Science ®Google Scholar
• Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR, Testa JR. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res. 2012;10(9):1178–88. doi:10.1158/1541-7786.MCR-12-0082.
   PubMed Web of Science ®Google Scholar
• Motwani M, Li DQ, Horvath A, Kumar R. Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling. PLoS One. 2013;8(8):e66585. doi:10.1371/journal.pone.0066585.
   PubMed Web of Science ®Google Scholar
• Li DQ, Nair SS, Ohshiro K, Kumar A, Nair VS, Pakala SB, et al. MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell Rep. 2012;2(6):1657–69. doi:10.1016/j.celrep.2012.11.018.
   PubMed Web of Science ®Google Scholar
• Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, et al. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget. 2016;7(47):76590–603. doi:10.18632/oncotarget.12576.
   PubMedGoogle Scholar